Selecta Biosciences Inc (SELB) Announces Earnings Results, Misses Estimates By $0.52 EPS

Selecta Biosciences Inc (NASDAQ:SELB) issued its quarterly earnings results on Monday. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.52. The business earned $2.93 million during the quarter, compared to analysts’ expectations of $15 million.

Selecta Biosciences (NASDAQ:SELB) opened at 13.88 on Friday. The firm has a 50-day moving average price of $13.58 and a 200 day moving average price of $16.53. Selecta Biosciences has a 52 week low of $10.26 and a 52 week high of $28.00.

SELB has been the topic of several recent analyst reports. Zacks Investment Research raised Selecta Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Wednesday, January 11th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Selecta Biosciences in a research note on Tuesday, March 28th.

In other news, COO Lloyd P. Johnston sold 13,205 shares of the firm’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $13.95, for a total transaction of $184,209.75. Following the sale, the chief operating officer now directly owns 14,811 shares in the company, valued at approximately $206,613.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Large investors have recently bought and sold shares of the stock. Candriam Luxembourg S.C.A. acquired a new stake in Selecta Biosciences during the first quarter worth approximately $444,000. State Street Corp acquired a new stake in Selecta Biosciences during the fourth quarter worth approximately $1,195,000. Perceptive Advisors LLC acquired a new stake in Selecta Biosciences during the fourth quarter worth approximately $2,433,000. Baker BROS. Advisors LP acquired a new stake in Selecta Biosciences during the third quarter worth approximately $2,550,000. Finally, Sphera Funds Management LTD. acquired a new stake in Selecta Biosciences during the third quarter worth approximately $3,989,000. Hedge funds and other institutional investors own 41.74% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Selecta Biosciences Inc (SELB) Announces Earnings Results, Misses Estimates By $0.52 EPS” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/04/22/selecta-biosciences-inc-selb-announces-earnings-results-misses-estimates-by-0-52-eps.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.